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Abstract
Background: Continuous glucose monitoring using subcutaneous sensors has been validated in adults and
children with diabetes, and was found to be useful in the management of glucose control. We aimed to assess
feasibility and reliability of a new continuous glucose monitoring system (CGMS) in a population of preterm
neonates using a Clarke error grid (CEG) specifically modified for preterm infants.
Methods: Preterm infants were recruited within 24 h from delivery. A subcutaneous sensor connected to a CGMS
was inserted and maintained for 6 days. Data collected from CGMS were compared with data obtained using a
glucometer. Management of the infants followed standard protocols and was not influenced by CGMS readings.
Results: Twenty patients (9 males) were included. Median (range) gestational age was 32 weeks (27–36) and
median (range) birth weight was 1350 g (860–3360). Average CGMS recording time was 137 h, for a total of 449
paired glucose levels. CEG and modified CEG criteria for clinical significance were met.
Conclusion: CGMS is a safe and clinically adequate method to estimate glucose levels in preterm infants. As the
glucose level can be evaluated in real time, this CGMS could be useful to reduce the number of heel sticks, to
observe glycaemic trends and to promptly detect episodes of both hypo- and hyper-glycaemia.
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Background
Preterm newborns are particularly exposed to blood glu-
cose levels fluctuations after birth, and their developing
brain is thought to be more susceptible to episodes of
both hypo- and hyper-glycaemia [1]. Such episodes,
although asymptomatic, usually occur during the first
week of life and are often clinically relevant. Symptomatic
hypoglycaemia has been associated with poor neurodeve-
lopmental outcome [1, 2]. Despite the relevance of these
metabolic alterations, their assessment is still hindered by
the lack of appropriate tools to monitor glucose levels
continuously [3, 4]. Plasma glucose levels, obtained
through enzymatic methods and performed in central la-
boratory facilities, remain the gold standard for glucose
assessment in the newborn [5]. This requires either re-
peated blood draws or manipulation of central lines,
which should be avoided in preterm infants in order to re-
duce risk of infections and anemia. Newborn infants at
high risk for dysglycaemia are usually monitored several
times per day, through finger-stick capillary blood and
point-of-care (POC) blood glucometer (GTX) [6]. Check-
ing blood glucose levels intermittently, however, could
lead to undetected episodes of altered glycaemia. For this
reason, continuous glucose monitoring systems (CGMSs)
using subcutaneous sensors have been validated in adults
and children with diabetes, and have been shown particu-
larly useful in the management of glucose control [7].
Three different devices have been approved by the US
Food and Drug Administration for continuous glucose
monitoring in newborns but none of them provides blood
glucose values in real time on the monitor [8, 9]. Medtro-
nic has recently produced a new generation instrument
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whose characteristics seem appropriate for neonatal in-
tensive care unit. The present study was designed to
assess feasibility and reliability of this new CGMS in
a population of preterm infants.
Methods
This non-randomized feasibility study was conducted be-
tween April 1, 2012 and September 30, 2012 in the neo-
natal intensive and sub-intensive care facilities of Catholic
University A. Gemelli Hospital following the approval of
our institutional review board. The following preterm in-
fants at increased risk for neonatal dyslycemia were eligible
for this study: intrauterine growth-restricted (IUGR) in-
fants, small for gestational age infants (SGA), very low birth
weight (VLBW) infants, extremely low birth weight
(ELBW) infants, infants of diabetic mothers, maternal treat-
ment with beta-blockers, tocolytics, oral hypoglycemic ther-
apy, large for gestational age (LGA) infants, asphyxiated
infants, septic infants, polycythaemic infants, infants with
feeding difficulties.
Infants with major congenital abnormalities at birth or
with skin diseases were excluded. Informed consent was
obtained from the parents, and infants enrolled were con-
nected to the CGMS (Medtronic, Northridge, Calif., USA)
within the first 24 h of life. Each bedside blood glucose test
was prescribed by the treating physician in accordance with
the standards of clinical practice currently followed inour
department. Management of the infants was not influenced
by the CGMS readings.
The CGMS is composed by the ENLITE sensor, the
Mini Link transmitter and the VEO monitor.
The ENLITE sensor has a cannula length of 8.75 mm
and it is a new generation sensor. No other studies about
CGMS reported the use of this device. It is equipped with a
glucose-oxidase which, in the presence of glucose in the
interstitial space, generates an electrical current every 10 s
and transmits wirelessly it through a Mini Link transmitter
to the VEO monitor that calculates the average of the cur-
rents measured every 5 min. The measuring principle is
based on the generation, by the enzymatic activity of
glucose-oxidase, of hydrogen peroxide from glucose and
oxygen. The hydrogen peroxide is then oxidized by a spe-
cific electrode that triggers the movement of electrons. The
measured current is then converted into an estimate of
blood glucose through the calibration procedure. The sys-
tem requires to be calibrated at least every 12 h, using the
glucometer blood glucose values. The interstitial glucose
concentration values are expressed in mg/dl in a range be-
tween 40 mg/dl (2.2 mmol/l) and 430 mg/dl (24 mmol/l),
and values that do not fall within this range are expressed
respectively as <40 mg/dl or >430 mg/dl while the VEO
monitor gives a sound alarm. Data are monitored and
showed in real time. Insertion procedure involves identifi-
cation of an unharmed skin area in the lateral part of the
thigh and application of a 2.5 % Lidocaine – 2.5 % Prilo-
caine ointment over that area 30 min before insertion of
thesensor ENLITE. The sensor is introduced following a
sterile procedure and then connectedto the MINILINK
transmitter.
The personal and clinical data of each patient were
collected in a dedicated database. Values recorded
through the continuous monitoring software were
downloaded via Care Link TM after sensor removal.
Hypoglycaemia was defined as a glucose value ≤45 mg/dl
[10–12], and hyperglycaemia as a glucose value ≥180 mg/
dl [13]. Data obtained with the CGMS were compared
with those obtained by GTX. We preferred a point of care
method, GTX, as a comparison, to a more accurate
laboratory method, because the first is the most used in
clinical practice in the NICU.
Statistics
As this was a feasibility study no formal sample size cal-
culation could be applied. To visualize the agreement
between the two measuring techniques we used the
Bland-Altman plot, and the Clarke Error Grid (CEG)
[14]. The CEG was specifically modified in order to be
clinically relevant in the management of dysglycaemia in
preterm infants.
Definitions of neonatal hypoglycemia and hypergly-
cemia requiring a therapeutic treatment were used to
obtain modified CEG.
CEG evaluates the accuracy of a new tool, as com-
pared to a standard method, for the determination of
glycaemia in a clinical setting. It shows the value gener-
ated by the monitoring system being tested along the or-
dinate axis, and the measurement of glucose as obtained
with the reference technique along the abscissa axis. The
CEG identifies 5 areas with different error in accuracy
combined with the severity of clinical consequences.
Region A: values within 20 % of the reference sensor.
Region B: values outside 20 % of the reference sensor,
but that would not lead to an inappropriate treatment.
Region C: values leading to an unnecessary treatment.
Region D: values indicating a potentially dangerous
failure to detect hypo- or hyper-glycaemia.
Region E: values that would confuse treatment of
hypoglycemia for hyperglycemia, and vice-versa.
Reference blood glucose levels in the standard CEG
are those generally used in adult or pediatric patients.
For this reason we chose to modify the grid according to
the blood glucose levels used in the clinical management
of newborn infants. In this modified Clarke error
grid (MCEG) we set the limit for the diagnosis of
hypoglycemia at 45 mg/dl, and the limit for the diagno-
sis of hyperglycemia to 180 mg/dl, because these values
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require therapeutic measures in the neonates, regardless
of gestational age of the baby. As a consequence, the
geometry of the region C upper size appears different
from the original CEG.
Results
The study population consisted of 20 infants, 9 males
and 11 females, with a median gestational age of
32 weeks (range 27–36 weeks) and median birth
weight of 1350 g (range 860 to 3360 g). The sensor
was held in place with an average duration of 137 h.
Nine patients were monitored performing 2 calibra-
tion procedures per day (every12 h), and 11 patients
by performing 3 calibrations per day (every 8 h). An
average number of 1637 measurements of blood glu-
cose concentration from the interstitial spacewere ob-
tained for each patient. On all 20 patients it was
possible to obtain 449 pairs of VEO vs. GTX
measurements.
Figure 1 reports the Bland Altman Analyses for all
glucose measurements. The mean (95 % CI) differ-
ence was −6,8 (−37,4 to 23,8) mg/dl. The instrument
shows a slight tendency to underestimate the value of
blood glucose.
Figure 2 reports the standard CEG and the MCEG. In
the CEG, 78,2 % of measurements falls in region A,
20,0 % of measurements falls in region B, and 1,78 % of
measurements in region D, without any value in region
C or E. Differently, the MCEG shows 72,6 % of measure-
ments in region A, 26,7 % of measurements in region B,
0,67 % of measurements in Region D and, again, not a
single value falls in either region C or E. In order to
evaluate whether sensor accuracy was influenced by ges-
tational age, birth weight and number of calibrations, we
carried out a subgroups analysis. The average error for
the subgroups and the p value (Student t test and
ANOVA) were evaluated. No statistically significant dif-
ferences between the subgroups were identified (Fig. 3).































Fig. 1 Bland Altman plot. CGMS vs GTX
































Fig. 2 Clarke Error Grid CGMS vs GTX (a) MCEG CGMS vs GTX (b)
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the study did not fall under the lower limit tested by
CGMS.
Discussion
We have tested a new generation device (CGMS,
MiniMed, Medtronic, Northridge, Calif., USA) to con-
tinuously monitor blood glucose in preterm infants at
risk of dysglycaemia. Three CGMS have already been
tested in clinical practice and have been approved by
the US Food and Drug Administration in newborns:
DexCom Seven (DexCom Inc.), Guardian RT (Medtronic
Diabetes, Inc.), and Navigator 40 (Abbott Diabetes). None
of them, although, provides blood glucose values in real
time on the monitor and uses the Enlite sensor, which
seems to be more suitable for preterm infants [8, 9].
Bearsdall et al. performed a CEG comparing glucose
values obtained from a previous Medtronic device with
values obtained from different POC blood glucose tests
and found great correlation between the two methods
[15]. However, the standard CEG was firstly used to test
the accuracy of blood glucose measurement in adults or
children with diabetes [14]. Therefore, as pointed out by
the same authors, the interpretation of these results in
the setting of neonates with different interventional glu-
cose levels needs to be cautious [15]. To our knowledge,
this is the first report of a comparison between blood
glucose values obtained via CGMS and via GTX using a
specifically modified CEG, more suitable for preterm in-
fants in the first days of life. Our results confirm a good
correlation between CGMS and POC GTX, based on the
established criteria that >95 % of all readings must be in
either zone A or B. There is no evidence, in fact, in the
MCEG, of an increase of the measurements into zones
(C, D, E), that would lead to inadequate management of
hyper- or hypo-glycaemia.
These data suggest that the CGMS is a clinically
accurate instrument to evaluate blood glucose levels in
preterm infants.
Our Bland Altman analyses for all glucose levels demon-
strated that the CGMS slightly under-reads as compared
to POC GTX, as has been previously reported [16, 17].
The new ENLITE sensor transfers a wireless signal dir-
ectly to the VEO monitor, providing real time evaluation
of blood glucose values. Out data suggest that, once the
sensor is in place, 2 POC determination of blood glucose
per day appear to be sufficient to calibrate the CGMS.
We believe that this new CGMS has a great potential in
reducing the number of heel sticks the newborn has to
undergo for routine glucose determination.
The application of the sensor appeared to be safe and
well tolerated, infants appeared to be unconcerned by its
continuous presence throughout the study period. It
remained effective after up to six days after positioning
and it did not interfere with nursing care. Although there
could be concerns about the use of this sensor in babies
with very delicate skin, no evidence of significant tissue
damage after placement for up to six days has been noted.
Previous studies showed that CGMS data correlates
well with point of care devices, with minimal bias. We
believe however that the clinical advantage of the use of
CGMS in preterm infants would not be based on
Fig. 3 Subgroups analysis. a 2 vs 3 daily calibrations. b Gestational
age soubgroups. c Birth weight soubgroups. Central bars indicate
the average error. Range, upper and lower limits, and P values are
also shown
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providing accurate single values but on showing a con-
tinuous information on trends of glucose control. This
could lead to select the cases actually deserving a blood
sample, limiting them only when really necessary, thus op-
timizing glucose control in preterm infants.
An important limit of the instrument is to provide
measurements of blood glucose only in the range between
40 mg/dl (2.2 mmol/l) and 430 mg/dl (24 mmol/l), thus
reducing the possibility of its use for clinical management
of neonatal hypoglycaemia.
In effect, the value of continuous glucose monitoring
should not be the ability of it to diagnose hypoglycemia
but to give a warning of alterations in trends of glucose
control. The finding of a value <40 mg/dL should lead
to obtain a blood sample to assess the severity of
hypoglycemia.
A limitation of our study is the small size of the popu-
lation. However, the observational design of the study
permitted to specifically address the efficacy and safety
of the CGMS. In fact, we chose to compare blood
glucose data provided by VEO with values provided by a
single bedside glucometer, as opposed to other studies
that have used different POC devices and even different
kind of samples (capillary vs arterial sticks) [15].
We choose to include in our study preterm infants
needing tight glucose control because of the increased
risk of both hyperglycaemia and hypoglycaemia. Al-
though our results fall within the range of normal
glucose values, not allowing to prove the therapeutic
application of the instrument, they still enable us to
verify the feasibility and reliability of this new CGMS
in our population of preterm infants.
Anyway, since all our data were substantially within
the range of normal blood glucose concentrations and
since the CGMS we tested is not able to read glucose
levels lower than 40 mg/dl, further improvement of the
sensor is needed before it can become a fundamental
tool in the management of hypoglycemia. Despite these
limits, our study shows that the CGMS in preterm
infants allows caregivers to: 1) evaluate glucose concen-
tration (mg/dl or mmol/liter); 2) detect trends in glucose
levels (increasing, decreasing, or stationary); and 3)
evaluate rate of glucose modifications [18].
The clinical use of sensors for continuous glucose
monitoring could therefore improve management of
glucose control in neonatal intensive care units, avoiding
undetected pathological glucose fluctuations [19].
Conclusions
Continuous glucose monitoring using subcutaneous
sensors has been validated in adults and children with
diabetes, and was found to be useful in the management
of glucose control.
It is safe and reliable in preterm infants. It is useful to
reduce the number of heel sticks, to observe glycaemic
trends and to promptly detect episodes of both hypo-
and hyper-glycaemia.
Although the present data are promising, studies with
a larger population of preterm infants at increased risk
of both hyperglycemia and hypoglycaemia, evaluating
also abnormal glucose values, are required in order to
better establish safety, reliability and therapeutic applica-
tions of the CGMS.
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